Advertisement
Singapore markets open in 7 hours 53 minutes

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,058.48
    -12.07 (-0.24%)
     

  • Dow

    38,385.95
    -117.74 (-0.31%)
     

  • Nasdaq

    15,679.15
    -17.49 (-0.11%)
     

  • Bitcoin USD

    64,804.08
    -1,900.41 (-2.85%)
     

  • CMC Crypto 200

    1,397.29
    -26.81 (-1.88%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Gold

    2,338.50
    -3.60 (-0.15%)
     

  • Crude Oil

    82.72
    -0.64 (-0.77%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Novartis says buys Ziarco Group to expand skin care portfolio

Reuters

ZURICH (Reuters) - Novartis (NOVN.S) is buying privately held drugmaker Ziarco Group for an undisclosed sum to gain access to its investigational eczema medicine, the Swiss pharmaceutical giant said on Friday.

The acquisition adds UK-based Ziarco's once-daily oral H4 receptor antagonist, ZPL389, that is being developed for the chronic, itchy inflammatory skin condition to Novartis's existing portfolio of approved and investigational dermatological drugs.

"There is an unmet need for innovative, effective and safe oral treatment options for people living with eczema," Vasant Narasimhan, Novartis's head of drug development and chief medical officer, said in a statement.

(Reporting by John Miller)